TR
EN
Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie
Öz
Objective: Antimicrobial resistance is a severe global problem, causing both medical and economic results. Klebsiella pneumoniae (K. pneumoniae) is a gram-negative bacterium that plays a major role in these burdens due to its widespread resistance mechanisms. This study searchs for the synergy and antagonism between meropenem and gentamicin using the disk diffusion method and compares these findings with results from the checkerboard method. If the results are consistent, validating the reliability of the disk diffusion method, it could be a cost-effective alternative to other testing methods.
Methods: The checkerboard method is used to assess the interaction of two antimicrobial agents (synergistic, indifferent, or antagonistic) by preparing a grid of wells containing varying concentrations of the agents. The fractional inhibitory concentration index (FICI) is calculated to evaluate the combination's efficacy.
In the disc diffusion method, the antimicrobial activity of an agent is determined by placing discs soaked in the agent on an agar plate inoculated with bacteria. After incubation, the diameter of the inhibition zone is measured to assess susceptibility.
Results: No synergy or antagonism was detected in any of the 30 Klebsiella pneumaniae isolates by either method.
Conclusion: The disc diffusion method is a cost-effective and reliable alternative to other in vitro synergy tests, especially when facilities are limited.
Anahtar Kelimeler
Proje Numarası
1919B012216444
Kaynakça
- Guoying W, Guo Z, Xiaoyu C, Longxiang X, Hongju W. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020; 17(17): 6278. DOI: 10.3390/ijerph17176278
- Baykal A, Cöplü N, Simsek H, Esen B, Gür D. Kan İzolatı E. coli ve K.pneumoniae Suşlarında Genişlemiş Spektrumlu Beta-Laktamaz, KPC-Tip Karbapenemaz ve Plazmid Aracılı AmpC Beta-Laktamaz Varlığının Araştırılması. Mikrobiyol Bul. 2012; 46(2): 159-69. PMid: 22639305
- Karampatakis, T.; Tsergouli, K.; Behzadi, P. Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options. Antibiotics 2023, 12, 234. DOI: 10.3390/antibiotics12020234
- Elemam, J. Rahimian, W. Mandell. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clinical Infectious Diseases, Volume 49, Issue 2, 15 July 2009, Pages 271–274. DOI: 10.1086/600042
- Dennis J. Doorduijn, Suzan H.M. Rooijakkers, Willem van Schaik, Bart W. Bardoel. Complement resistance mechanisms of Klebsiella pneumoniae. Immunobiology. Volume 221, Issue 10, October 2016, Pages 1102-1109. DOI: 10.1016/j.imbio.2016.06.014
- Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and Economic Impact of Common Multidrug-resistant Gram-negative Bacilli. Antimicrob Agents Chemother. 2008;52(3):813–21. DOI: 10.1128/AAC.01169-07
- Martin, R.M.; Bachman, M.A. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front. Cell. Infect. Microbiol. 2018, 8, 4. DOI: 10.3389/fcimb.2018.00004
- Havan M, Kendirli T, Parlar ÖT, et al. Clinical Management of a Pandrug-Resistant OXA-48 Klebsiella pneumoniae Infection in the Pediatric Intensive Care Unit. Microb Drug Resist. 2023 Jun;29(6):256-262. DOI: 10.1089/mdr.2022.0247
Ayrıntılar
Birincil Dil
İngilizce
Konular
Tıbbi Mikrobiyoloji (Diğer)
Bölüm
Araştırma Makalesi
Erken Görünüm Tarihi
31 Aralık 2024
Yayımlanma Tarihi
31 Aralık 2024
Gönderilme Tarihi
23 Kasım 2024
Kabul Tarihi
27 Kasım 2024
Yayımlandığı Sayı
Yıl 2024 Cilt: 8 Sayı: 3
APA
Ünal, A., Tanrıverdi Çaycı, Y., & Bıyık, İ. (2024). Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie. Journal of Biotechnology and Strategic Health Research, 8(3), 236-241. https://doi.org/10.34084/bshr.1590089
AMA
1.Ünal A, Tanrıverdi Çaycı Y, Bıyık İ. Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie. J Biotechnol and Strategic Health Res. 2024;8(3):236-241. doi:10.34084/bshr.1590089
Chicago
Ünal, Ali, Yeliz Tanrıverdi Çaycı, ve İlknur Bıyık. 2024. “Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie”. Journal of Biotechnology and Strategic Health Research 8 (3): 236-41. https://doi.org/10.34084/bshr.1590089.
EndNote
Ünal A, Tanrıverdi Çaycı Y, Bıyık İ (01 Aralık 2024) Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie. Journal of Biotechnology and Strategic Health Research 8 3 236–241.
IEEE
[1]A. Ünal, Y. Tanrıverdi Çaycı, ve İ. Bıyık, “Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie”, J Biotechnol and Strategic Health Res, c. 8, sy 3, ss. 236–241, Ara. 2024, doi: 10.34084/bshr.1590089.
ISNAD
Ünal, Ali - Tanrıverdi Çaycı, Yeliz - Bıyık, İlknur. “Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie”. Journal of Biotechnology and Strategic Health Research 8/3 (01 Aralık 2024): 236-241. https://doi.org/10.34084/bshr.1590089.
JAMA
1.Ünal A, Tanrıverdi Çaycı Y, Bıyık İ. Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie. J Biotechnol and Strategic Health Res. 2024;8:236–241.
MLA
Ünal, Ali, vd. “Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie”. Journal of Biotechnology and Strategic Health Research, c. 8, sy 3, Aralık 2024, ss. 236-41, doi:10.34084/bshr.1590089.
Vancouver
1.Ali Ünal, Yeliz Tanrıverdi Çaycı, İlknur Bıyık. Evaluation of Meropenem and Gentamicin Synergy on Klebsiella pneumonaie. J Biotechnol and Strategic Health Res. 01 Aralık 2024;8(3):236-41. doi:10.34084/bshr.1590089